A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Crizotinib (Primary) ; Iobenguane (Primary) ; Aldesleukin; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide phosphate; Isotretinoin; Melphalan; Sargramostim; Thiotepa; Topotecan; Vincristine
- Indications Neuroblastoma
- Focus Therapeutic Use
- 25 May 2018 Planned End Date changed from 1 Mar 2022 to 28 Mar 2022.
- 25 May 2018 Planned primary completion date changed from 1 Mar 2022 to 28 Mar 2022.
- 25 May 2018 Status changed from not yet recruiting to recruiting.